Cargando…

Long-term follow up of Hodgkin lymphoma

BACKGROUND: Hodgkin lymphoma (HL) is the paradigm of curable disease. This study analyzed the overall survival (OS) of patients with HL and compared their survival between decades and with the expected survival of a general population. RESULTS: The median follow-up was 22 years. The median OS was 33...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez-Callejo, David, Zurutuza, Lorea, Royuela, Ana, Torrente, Maria, Núñez, Beatriz, Calvo, Virginia, Méndez, Miriam, Franco, Fernando, Brenes, María Auxiliadora, Sánchez, Juan Cristobal, Provencio, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837753/
https://www.ncbi.nlm.nih.gov/pubmed/29545926
http://dx.doi.org/10.18632/oncotarget.24392
_version_ 1783304141958807552
author Perez-Callejo, David
Zurutuza, Lorea
Royuela, Ana
Torrente, Maria
Núñez, Beatriz
Calvo, Virginia
Méndez, Miriam
Franco, Fernando
Brenes, María Auxiliadora
Sánchez, Juan Cristobal
Provencio, Mariano
author_facet Perez-Callejo, David
Zurutuza, Lorea
Royuela, Ana
Torrente, Maria
Núñez, Beatriz
Calvo, Virginia
Méndez, Miriam
Franco, Fernando
Brenes, María Auxiliadora
Sánchez, Juan Cristobal
Provencio, Mariano
author_sort Perez-Callejo, David
collection PubMed
description BACKGROUND: Hodgkin lymphoma (HL) is the paradigm of curable disease. This study analyzed the overall survival (OS) of patients with HL and compared their survival between decades and with the expected survival of a general population. RESULTS: The median follow-up was 22 years. The median OS was 33 years. The incidence mortality rate for all causes is 2 per every 100 patients per year. The OS of our cohort at 10 years from diagnosis was 76% (95% CI: 72–79) and 52% at 30 years (95% CI: 48–57). Overall SMR (1980–2013) was 2,943 (95% CI: 2,518–3,439). Excluding the primary tumor as the cause of death, the SMR obtained is 2,266 (95% CI: 1,895–2,710). The SMR for those patients diagnosed before the year 2000 was 2,097 (95% CI: 1,732–2,539); and for those diagnosed after 2000 was 5,218 (95% CI: 8,655). The group of patients diagnosed after 2000 had statistically significant more advanced stages, were older and less responsive to treatment. CONCLUSIONS: Despite the advances achieved, the risk of death remains higher than in the general population, mainly for those patients diagnosed after year 2000, even after almost 40 years of follow-up. This data might suggest a shift to more aggressive forms of disease in recent years. PATIENTS AND METHODS: A total of 595 patients diagnosed with HL were included between January 1966 and February 2014. The standardized mortality ratio (SMR) was analyzed using the annual rate of mortality in the general Spanish population, adjusted for age, sex and time period.
format Online
Article
Text
id pubmed-5837753
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-58377532018-03-15 Long-term follow up of Hodgkin lymphoma Perez-Callejo, David Zurutuza, Lorea Royuela, Ana Torrente, Maria Núñez, Beatriz Calvo, Virginia Méndez, Miriam Franco, Fernando Brenes, María Auxiliadora Sánchez, Juan Cristobal Provencio, Mariano Oncotarget Research Paper BACKGROUND: Hodgkin lymphoma (HL) is the paradigm of curable disease. This study analyzed the overall survival (OS) of patients with HL and compared their survival between decades and with the expected survival of a general population. RESULTS: The median follow-up was 22 years. The median OS was 33 years. The incidence mortality rate for all causes is 2 per every 100 patients per year. The OS of our cohort at 10 years from diagnosis was 76% (95% CI: 72–79) and 52% at 30 years (95% CI: 48–57). Overall SMR (1980–2013) was 2,943 (95% CI: 2,518–3,439). Excluding the primary tumor as the cause of death, the SMR obtained is 2,266 (95% CI: 1,895–2,710). The SMR for those patients diagnosed before the year 2000 was 2,097 (95% CI: 1,732–2,539); and for those diagnosed after 2000 was 5,218 (95% CI: 8,655). The group of patients diagnosed after 2000 had statistically significant more advanced stages, were older and less responsive to treatment. CONCLUSIONS: Despite the advances achieved, the risk of death remains higher than in the general population, mainly for those patients diagnosed after year 2000, even after almost 40 years of follow-up. This data might suggest a shift to more aggressive forms of disease in recent years. PATIENTS AND METHODS: A total of 595 patients diagnosed with HL were included between January 1966 and February 2014. The standardized mortality ratio (SMR) was analyzed using the annual rate of mortality in the general Spanish population, adjusted for age, sex and time period. Impact Journals LLC 2018-02-03 /pmc/articles/PMC5837753/ /pubmed/29545926 http://dx.doi.org/10.18632/oncotarget.24392 Text en Copyright: © 2018 Perez-Callejo et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Perez-Callejo, David
Zurutuza, Lorea
Royuela, Ana
Torrente, Maria
Núñez, Beatriz
Calvo, Virginia
Méndez, Miriam
Franco, Fernando
Brenes, María Auxiliadora
Sánchez, Juan Cristobal
Provencio, Mariano
Long-term follow up of Hodgkin lymphoma
title Long-term follow up of Hodgkin lymphoma
title_full Long-term follow up of Hodgkin lymphoma
title_fullStr Long-term follow up of Hodgkin lymphoma
title_full_unstemmed Long-term follow up of Hodgkin lymphoma
title_short Long-term follow up of Hodgkin lymphoma
title_sort long-term follow up of hodgkin lymphoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837753/
https://www.ncbi.nlm.nih.gov/pubmed/29545926
http://dx.doi.org/10.18632/oncotarget.24392
work_keys_str_mv AT perezcallejodavid longtermfollowupofhodgkinlymphoma
AT zurutuzalorea longtermfollowupofhodgkinlymphoma
AT royuelaana longtermfollowupofhodgkinlymphoma
AT torrentemaria longtermfollowupofhodgkinlymphoma
AT nunezbeatriz longtermfollowupofhodgkinlymphoma
AT calvovirginia longtermfollowupofhodgkinlymphoma
AT mendezmiriam longtermfollowupofhodgkinlymphoma
AT francofernando longtermfollowupofhodgkinlymphoma
AT brenesmariaauxiliadora longtermfollowupofhodgkinlymphoma
AT sanchezjuancristobal longtermfollowupofhodgkinlymphoma
AT provenciomariano longtermfollowupofhodgkinlymphoma